



# COMMONWEALTH of VIRGINIA

Department of Medical Assistance Services

## DRUG UTILIZATION REVIEW PROGRAM

Virginia Medicaid  
Drug Utilization Review (DUR) Board  
Quarterly Meeting  
2pm  
Thursday, September 12, 2013  
DMAS Board Room 13<sup>th</sup> Floor

### Agenda

1. Call to Order and Introductions – Randy Ferrance, MD, Chair
2. Minutes
  - a. Approval of Minutes from the May 16, 2013 meeting
3. New Drugs
  - a. Non-Self-Administered Medications
  - b. Self-Administered Medications
    1. Cystaran (cysteamine)
    2. Procysbi (cysteamine bitartrate)
    3. Invokana (canagliflozin)
    4. Liptruzet (ezetimibe and atorvastatin)
    5. Ospheña (ospemifene)
    6. Sirturo (bedaquiline)
    7. Tecfidera (dimethyl fumarate)
    8. Tobi Podhaler (tobramycin inhalation powder)
    9. Vecamyl (mecamylamine hydrochloride)
    10. Simbrinza (brinzolamide/brimonidine tartrate)
    11. Diclegis (doxylamine succinate and pyridoxine hcl)
    12. Namenda XR (memantine hydrochloride)
    13. Afinitor Disperz (everolimus)
    14. Simponi (golimumab)
    15. Tafinlar (dabrafenib)
    16. Belviq (lorcaserin hydrochloride)
    17. Doryx (doxycycline hyclate)
    18. Mekinist (trametinib)
    19. Suprax (cefixime)



# COMMONWEALTH of VIRGINIA

Department of Medical Assistance Services

## DRUG UTILIZATION REVIEW PROGRAM

20. Revlimid (lenalidomide)

4. Old Business
  - a. Ravicti
5. Reports
  - a. ProDUR
  - b. RetroDUR
  - c. Ad hocs
  - d. Utilization Analysis Reports based on Claims
6. Future Topics
7. Other Business
  - a. Truvada Update
  - b. Antipsychotics in Dementia
  - c. Octreotide Numbers
  - d. AAP Historical Report
  - e. Bisphosphonate
    1. Xerox Data
    2. DMAS Data
8. Adjournment